|
Concerns About Acute Cholecystitis in Patients on GLP-1 RAs
|
|
Based on a series of adverse events reported to the FDA, which were in line with other research, the agency has revised prescribing information for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to include information about acute gallbladder events. According to events reported to the FDA, some patients have died from adverse effects. Learn more about what researchers have to say.
|
|
|
Here's What Future COVID-19 Response Might Look Like
|
|
|
In addition to the annual flu shot season, pharmacists might have to gear up for an annual COVID-19 shot season at the same or different time. That was the prediction of officials at a recent White House COVID-19 briefing. Find out why they predicted yearly vaccines against the novel coronavirus for most Americans, with certain vulnerable groups being boosted more frequently.
|
|
Turning Point in How Customers Use Retail Pharmacies
|
|
|
Acceptance of receiving health and wellness services, including vaccines, at pharmacies has grown over the last several years. In fact, a new J.D. Power survey pointed out that the majority of customers visiting pharmacies used those extra services as well as shopping and filling prescriptions. That led to a rise in customer satisfaction, as well. Read more.
|
|
|
When Should IV KENGREAL (cangrelor) Be Used in the Cath Lab?
|
|
The 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization has a specific recommendation: In patients undergoing percutaneous coronary intervention who are P2Y12-inhibitor naive, IV cangrelor may be reasonable to reduce periprocedural ischemic events (Class of Recommendation 2b with level of evidence B from randomized clinical trials). Read more.
|
|
